Financing - May 24, 2023
Gedea Biotech raises 1.3 million EUR
The money has been raised for additional development activities of their product pHyph for antibiotic free treatment of vaginal infections. The funds will be used for an ongoing proof-of-concept study for the treatment of Vulvo Vaginal Candidiasis (VVC) with pHyph, partially financed by a recent grant from Swelife and Medtech4Health, investigating how the vaginal microbiome […]
Biotech Business - May 23, 2023
BioLamina announces release of first batches from new facility
BioLamina announces the release of the first Biolaminin 521 LN batches issued from its new manufacturing facility in Sundbyberg, Sweden. The products, which are now ready for commercialization, have been produced in the latest expansion of BioLamina premises. This facility is dedicated to production and research within process development, matrix biology and cellular assays. The […]
Acquisition - May 10, 2023
Sobi to acquire CTI BioPharma for 1.7 billion USD
Swedish Orphan Biovitrum (Sobi) has entered into an agreement and plan of merger with CTI BioPharma (CTI) under which Sobi has agreed to acquire CTI, by means of a tender offer. Sobi is to commence a cash tender offer to acquire all issued and outstanding shares of CTI for USD 9.10 per share, corresponding to […]
Biotech Business - May 10, 2023
AstraZeneca’s Koselugo approved in China
Koselugo (selumetinib) has been approved in China for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in paediatric patients with neurofibromatosis type 1 (NF1) aged three years and above. “Koselugo offers hope for children whose quality of life and overall well-being is impacted by the growth of painful, debilitating tumours throughout the body. We are […]
Agreement - May 4, 2023
XNK Therapeutics in agreement with global pharma company
The company’s autologous natural killer (NK) cell therapy candidate XNK04 will be evaluated in combination with an ADCC competent PD-L1 inhibitor in liver cancer under a research agreement with a global pharma company. The preclinical validation study aims to test the cell therapy candidate XNK04 alone and in combination with an antibody checkpoint inhibitor against […]
Biotech Business - April 26, 2023
Xbrane and STADA supply Ximluci in England
The two companies are now supplying Ximluci (ranibizumab biosimilar) in England via a National Health Service (NHS) England Framework Agreement. The partners announced in January 2023 that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) had granted a marketing authorization for Ximluci (ranibizumab), a biosimilar referencing Lucentis. Under the co-development agreement in operation since […]
